Lipoprotein metabolism, dyslipidemia, and nonalcoholic fatty liver disease

Seminars in Liver Disease

Volumn 33, Issue 4, 2013, Pages 380-388

  Cohen, David E ^a   Fisher, Edward A ^b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

apolipoprotein; cardiovascular disease; cholesterol; insulin resistance; triglycerides

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; CHOLESTEROL; CHOLESTEROL ESTER; CHOLESTEROL ESTER TRANSFER PROTEIN; CHYLOMICRON; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERMEDIATE DENSITY LIPOPROTEIN; LIPOPROTEIN; LIPOPROTEIN LIPASE; LIVER TRIACYLGLYCEROL LIPASE; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; PHOSPHATIDYLCHOLINE STEROL ACYLTRANSFERASE; PHOSPHOLIPID TRANSFER PROTEIN; PROTEOHEPARAN SULFATE; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ADIPOSE TISSUE; ARTICLE; ATHEROGENESIS; AUTOPHAGOSOME; CHOLESTEROL LIVER LEVEL; CHOLESTEROL TRANSPORT; DYSLIPIDEMIA; HUMAN; INSULIN RESISTANCE; LIPID TRANSPORT; LIPOPROTEIN BLOOD LEVEL; LIPOPROTEIN METABOLISM; LIVER; MORBIDITY; MORTALITY; NONALCOHOLIC FATTY LIVER; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN SECRETION; PROTEIN STRUCTURE; TRIACYLGLYCEROL BLOOD LEVEL;

ANIMALS; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CHOLESTEROL; DYSLIPIDEMIAS; FATTY LIVER; HUMANS; INSULIN RESISTANCE; LIPOPROTEINS; LIVER; PROGNOSIS; RISK FACTORS; TRIGLYCERIDES;

EID: 84887591688     PISSN: 02728087     EISSN: 10988971     Source Type: Journal    
DOI: 10.1055/s-0033-1358519     Document Type: Article

References (97)

1. Ekstedt M., Franzén L. E., Mathiesen U. L., et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology: 2006; 44 4 865 873
2. Vanwagner L. B., Bhave M., Te H. S., Feinglass J., Alvarez L., Rinella M. E. Patients transplanted for nonalcoholic steatohepatitis are at increased risk for postoperative cardiovascular events. Hepatology: 2012; 56 5 1741 1750
3. Kim D., Kim W. R., Kim H. J., Therneau T. M. Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States. Hepatology: 2013; 57 4 1357 1365
4. Chatrath H., Vuppalanchi R., Chalasani N. Dyslipidemia in patients with nonalcoholic fatty liver disease. Semin Liver Dis: 2012; 32 1 22 29
5. Treeprasertsuk S., Leverage S., Adams L. A., Lindor K. D., St Sauver J., Angulo P. The Framingham risk score and heart disease in nonalcoholic fatty liver disease. Liver Int: 2012; 32 6 945 950
6. Choi S. H., Ginsberg H. N. Increased very low density lipoprotein (VLDL) secretion, hepatic steatosis, and insulin resistance. Trends Endocrinol Metab: 2011; 22 9 353 363
7. Tilg H., Hotamisligil G. S. Nonalcoholic fatty liver disease: cytokine-adipokine interplay and regulation of insulin resistance. Gastroenterology: 2006; 131 3 934 945
8. Targher G., Day C. P., Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med: 2010; 363 14 1341 1350
9. Musso G., Cassader M., Gambino R. Diagnostic accuracy of adipose insulin resistance index and visceral adiposity index for progressive liver histology and cardiovascular risk in nonalcoholic fatty liver disease. Hepatology: 2012; 56 2 788 789
10. Gupte P., Amarapurkar D., Agal S., et al. Non-alcoholic steatohepatitis in type 2 diabetes mellitus. J Gastroenterol Hepatol: 2004; 19 8 854 858
11. Tolman K. G., Fonseca V., Tan M. H., Dalpiaz A. Narrative review: hepatobiliary disease in type 2 diabetes mellitus. Ann Intern Med: 2004; 141 12 946 956
12. Assy N., Kaita K., Mymin D., Levy C., Rosser B., Minuk G. Fatty infiltration of liver in hyperlipidemic patients. Dig Dis Sci: 2000; 45 10 1929 1934
13. Speliotes E. K., Massaro J. M., Hoffmann U., et al. Fatty liver is associated with dyslipidemia and dysglycemia independent of visceral fat: the Framingham Heart Study. Hepatology: 2010; 51 6 1979 1987
14. Lomonaco R., Chen J., Cusi K. An endocrine perspective of nonalcoholic fatty liver disease (NAFLD). Ther Adv Endocrinol Metab: 2011; 2 5 211 225
15. DeFilippis A. P., Blaha M. J., Martin S. S., et al. Nonalcoholic fatty liver disease and serum lipoproteins: the Multi-Ethnic Study of Atherosclerosis. Atherosclerosis: 2013; 227 2 429 436
16. Small D. M. The Physical Chemistry of Lipids. From Alkanes to Phospholipids. New York, NY Plenum Press: 1986
17. Jonas A. Lipoprotein structure. In: Vance D. E., Vance J. E., eds. Biochemistry of Lipids, Lipoproteins and Membranes. 4th ed. Amsterdam, The Netherlands Elsevier: 2002; 483 404
18. Cohen D. E. Lipoprotein metabolism and cholesterol balance. In: Arias I. M., Alter H., Boyer J. L., Cohen D. E., Fausto N., Shafritz D. A., Wolkoff A. W., eds. The Liver: Biology and Pathobiology. 5th ed. Oxford, UK Wiley Blackwell: 2009; 271 285
19. Iqbal J., Hussain M. M. Intestinal lipid absorption. Am J Physiol Endocrinol Metab: 2009; 296 6 E1183 E1194
20. Rudel L. L., Lee R. G., Parini P. ACAT2 is a target for treatment of coronary heart disease associated with hypercholesterolemia. Arterioscler Thromb Vasc Biol: 2005; 25 6 1112 1118
21. Rutledge A. C., Su Q., Adeli K. Apolipoprotein B100 biogenesis: a complex array of intracellular mechanisms regulating folding, stability, and lipoprotein assembly. Biochem Cell Biol: 2010; 88 2 251 267
22. Fisher E. A., Ginsberg H. N. Complexity in the secretory pathway: the assembly and secretion of apolipoprotein B-containing lipoproteins. J Biol Chem: 2002; 277 20 17377 17380
23. Hussain M. M., Shi J., Dreizen P. Microsomal triglyceride transfer protein and its role in apoB-lipoprotein assembly. J Lipid Res: 2003; 44 1 22 32
24. Chamberlain J. M., O'Dell C., Sparks C. E., Sparks J. D. Insulin suppression of apolipoprotein B in McArdle RH7777 cells involves increased sortilin 1 interaction and lysosomal targeting. Biochem Biophys Res Commun: 2013; 430 1 66 71
25. Yao Z., Wang Y. Apolipoprotein C-III and hepatic triglyceride-rich lipoprotein production. Curr Opin Lipidol: 2012; 23 3 206 212
26. Wetterau J. R., Aggerbeck L. P., Bouma M. E., et al. Absence of microsomal triglyceride transfer protein in individuals with abetalipoproteinemia. Science: 1992; 258 5084 999 1001
27. Berriot-Varoqueaux N., Aggerbeck L. P., Samson-Bouma M., Wetterau J. R. The role of the microsomal triglyceride transfer protein in abetalipoproteinemia. Annu Rev Nutr: 2000; 20 663 697
28. Cuchel M., Bloedon L. T., Szapary P. O., et al. Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia. N Engl J Med: 2007; 356 2 148 156
29. Goh V. J., Silver D. L. The lipid droplet as a potential therapeutic target in NAFLD. Semin Liver Dis: 2013;; In press
30. Romeo S., Kozlitina J., Xing C., et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet: 2008; 40 12 1461 1465
31. Cohen J. C., Horton J. D., Hobbs H. H. Human fatty liver disease: old questions and new insights. Science: 2011; 332 6037 1519 1523
32. Sookoian S., Pirola C. J. Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease. Hepatology: 2011; 53 6 1883 1894
33. Chamoun Z., Vacca F., Parton R. G., Gruenberg J. PNPLA3/adiponutrin functions in lipid droplet formation. Biol Cell: 2013; 105 5 219 233
34. Li J. Z., Huang Y., Karaman R., et al. Chronic overexpression of PNPLA3I148M in mouse liver causes hepatic steatosis. J Clin Invest: 2012; 122 11 4130 4144
35. Pirazzi C., Adiels M., Burza M. A., et al. Patatin-like phospholipase domain-containing 3 (PNPLA3) I148M (rs738409) affects hepatic VLDL secretion in humans and in vitro. J Hepatol: 2012; 57 6 1276 1282
36. Tanoli T., Yue P., Yablonskiy D., Schonfeld G. Fatty liver in familial hypobetalipoproteinemia: roles of the APOB defects, intra-abdominal adipose tissue, and insulin sensitivity. J Lipid Res: 2004; 45 5 941 947
37. McGowan M. P., Tardif J. C., Ceska R., et al. Randomized, placebo-controlled trial of mipomersen in patients with severe hypercholesterolemia receiving maximally tolerated lipid-lowering therapy. PLoS ONE: 2012; 7 11 e49006
38. Pan M., Cederbaum A. I., Zhang Y. L., Ginsberg H. N., Williams K. J., Fisher E. A. Lipid peroxidation and oxidant stress regulate hepatic apolipoprotein B degradation and VLDL production. J Clin Invest: 2004; 113 9 1277 1287
39. Brodsky J. L., Fisher E. A. The many intersecting pathways underlying apolipoprotein B secretion and degradation. Trends Endocrinol Metab: 2008; 19 7 254 259
40. Fisher E. A. The degradation of apolipoprotein B100: multiple opportunities to regulate VLDL triglyceride production by different proteolytic pathways. Biochim Biophys Acta: 2012; 1821 5 778 781
41. Strong A., Ding Q., Edmondson A. C., et al. Hepatic sortilin regulates both apolipoprotein B secretion and LDL catabolism. J Clin Invest: 2012; 122 8 2807 2816
42. Haas M. E., Attie A. D., Biddinger S. B. The regulation of ApoB metabolism by insulin. Trends Endocrinol Metab: 2013; 24 8 391 397
43. Kawano Y., Cohen D. E. Mechanisms of hepatic triglyceride accumulation in non-alcoholic fatty liver disease. J Gastroenterol: 2013; 48 4 434 441
44. Xu X., So J-S, Park J-G, Lee A-H. Transcriptional control of hepatic lipid metabolism by SREBP and ChREBP. Semin Liver Dis: 2013;; In press
45. Uyeda K., Repa J. J. Carbohydrate response element binding protein, ChREBP, a transcription factor coupling hepatic glucose utilization and lipid synthesis. Cell Metab: 2006; 4 2 107 110
46. Sparks C. E., Sparks J. D. Hepatic steatosis and VLDL hypersecretion. Curr Opin Lipidol: 2012; 23 4 395 397
47. Lee A. H., Scapa E. F., Cohen D. E., Glimcher L. H. Regulation of hepatic lipogenesis by the transcription factor XBP1. Science: 2008; 320 5882 1492 1496
48. Henkel A., Green R. M. The unfolded protein response in fatty liver disease. Semin Liver Dis: 2013;; In press
49. Shachter N. S. Apolipoproteins C-I and C-III as important modulators of lipoprotein metabolism. Curr Opin Lipidol: 2001; 12 3 297 304
50. Fielding P. E., Fielding C. J. Dynamics of lipoprotein transport in the human circulatory system. In: Vance D. E., Vance J. E., eds. Biochemistry of Lipids, Lipoproteins and Membranes. 4th ed. Amsterdam, The Netherlands Elsevier: 2002; 527 552
51. Merkel M., Eckel R. H., Goldberg I. J. Lipoprotein lipase: genetics, lipid uptake, and regulation. J Lipid Res: 2002; 43 12 1997 2006
52. Young S. G., Zechner R. Biochemistry and pathophysiology of intravascular and intracellular lipolysis. Genes Dev: 2013; 27 5 459 484
53. Wang H., Eckel R. H. Lipoprotein lipase: from gene to obesity. Am J Physiol Endocrinol Metab: 2009; 297 2 E271 E288
54. Mead J. R., Irvine S. A., Ramji D. P. Lipoprotein lipase: structure, function, regulation, and role in disease. J Mol Med (Berl): 2002; 80 12 753 769
55. Cohn J. S., Patterson B. W., Uffelman K. D., Davignon J., Steiner G. Rate of production of plasma and very-low-density lipoprotein (VLDL) apolipoprotein C-III is strongly related to the concentration and level of production of VLDL triglyceride in male subjects with different body weights and levels of insulin sensitivity. J Clin Endocrinol Metab: 2004; 89 8 3949 3955
56. Cooper A. D. Hepatic uptake of chylomicron remnants. J Lipid Res: 1997; 38 11 2173 2192
57. Mahley R. W., Ji Z. S. Remnant lipoprotein metabolism: key pathways involving cell-surface heparan sulfate proteoglycans and apolipoprotein E. J Lipid Res: 1999; 40 1 1 16
58. Mahley R. W., Rall S. C. Jr. Apolipoprotein E: far more than a lipid transport protein. Annu Rev Genomics Hum Genet: 2000; 1 507 537
59. Packard C. J., Shepherd J. Lipoprotein heterogeneity and apolipoprotein B metabolism. Arterioscler Thromb Vasc Biol: 1997; 17 12 3542 3556
60. Lewis G. F., Murdoch S., Uffelman K., et al. Hepatic lipase mRNA, protein, and plasma enzyme activity is increased in the insulin-resistant, fructose-fed Syrian golden hamster and is partially normalized by the insulin sensitizer rosiglitazone. Diabetes: 2004; 53 11 2893 2900
61. Miksztowicz V., Lucero D., Zago V., et al. Hepatic lipase activity is increased in non-alcoholic fatty liver disease beyond insulin resistance. Diabetes Metab Res Rev: 2012; 28 6 535 541
62. Lucero D., Zago V., López G. I., et al. Does non-alcoholic fatty liver impair alterations of plasma lipoproteins and associated factors in metabolic syndrome? Clin Chim Acta: 2011; 412 7-8 587 592
63. Schneider W. J. Lipoprotein receptors. In: Vance D. E., ed. Biochemistry of Lipids, Lipoproteins and Membranes. Amsterdam, The Netherlands Elsevier: 2002; 553 572
64. Lambert G., Sjouke B., Choque B., Kastelein J. J., Hovingh G. K. The PCSK9 decade. J Lipid Res: 2012; 53 12 2515 2524
65. Jiang Z. G., Robson S. C., Yao Z. Lipoprotein metabolism in nonalcoholic fatty liver disease. J Biomed Res: 2013; 27 1 1 13
66. Brown M. S., Goldstein J. L. A receptor-mediated pathway for cholesterol homeostasis. Science: 1986; 232 4746 34 47
67. Goldstein J. L., Brown M. S. The LDL receptor. Arterioscler Thromb Vasc Biol: 2009; 29 4 431 438
68. Kwon H. J., Abi-Mosleh L., Wang M. L., et al. Structure of N-terminal domain of NPC1 reveals distinct subdomains for binding and transfer of cholesterol. Cell: 2009; 137 7 1213 1224
69. Horton J. D., Goldstein J. L., Brown M. S. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest: 2002; 109 9 1125 1131
70. Radhakrishnan A., Goldstein J. L., McDonald J. G., Brown M. S. Switch-like control of SREBP-2 transport triggered by small changes in ER cholesterol: a delicate balance. Cell Metab: 2008; 8 6 512 521
71. Puri P., Baillie R. A., Wiest M. M., et al. A lipidomic analysis of nonalcoholic fatty liver disease. Hepatology: 2007; 46 4 1081 1090
72. Min H. K., Kapoor A., Fuchs M., et al. Increased hepatic synthesis and dysregulation of cholesterol metabolism is associated with the severity of nonalcoholic fatty liver disease. Cell Metab: 2012; 15 5 665 674
73. Cohen D. E. Pathogenesis of gallstones. In: Zakim D., Boyer T. D., eds. Hepatology: A Textbook of Liver Disease. 4 ed. Philadelphia, PA WB Saunders: 2002; 1713 1743
74. Lewis G. F., Rader D. J. New insights into the regulation of HDL metabolism and reverse cholesterol transport. Circ Res: 2005; 96 12 1221 1232
75. Silver D. L., Jiang X. C., Arai T., Bruce C., Tall A. R. Receptors and lipid transfer proteins in HDL metabolism. Ann N Y Acad Sci: 2000; 902 103 111, discussion 111-112
76. Glomset J. A. The plasma lecithins:cholesterol acyltransferase reaction. J Lipid Res: 1968; 9 2 155 167
77. Fisher E. A., Feig J. E., Hewing B., Hazen S. L., Smith J. D. High-density lipoprotein function, dysfunction, and reverse cholesterol transport. Arterioscler Thromb Vasc Biol: 2012; 32 12 2813 2820
78. Timmins J. M., Lee J. Y., Boudyguina E., et al. Targeted inactivation of hepatic Abca1 causes profound hypoalphalipoproteinemia and kidney hypercatabolism of apoA-I. J Clin Invest: 2005; 115 5 1333 1342
79. Zannis V. I., Chroni A., Krieger M. Role of apoA-I, ABCA1, LCAT, and SR-BI in the biogenesis of HDL. J Mol Med (Berl): 2006; 84 4 276 294
80. Blanco-Vaca F., Escolà-Gil J. C., Martín-Campos J. M., Julve J. Role of apoA-II in lipid metabolism and atherosclerosis: advances in the study of an enigmatic protein. J Lipid Res: 2001; 42 11 1727 1739
81. Kiss R. S., McManus D. C., Franklin V., et al. The lipidation by hepatocytes of human apolipoprotein A-I occurs by both ABCA1-dependent and -independent pathways. J Biol Chem: 2003; 278 12 10119 10127
82. Webb N. R., Cai L., Ziemba K. S., et al. The fate of HDL particles in vivo after SR-BI-mediated selective lipid uptake. J Lipid Res: 2002; 43 11 1890 1898
83. Rye K. A., Barter P. J. Formation and metabolism of prebeta-migrating, lipid-poor apolipoprotein A-I. Arterioscler Thromb Vasc Biol: 2004; 24 3 421 428
84. Yancey P. G., Bortnick A. E., Kellner-Weibel G., de la Llera-Moya M., Phillips M. C., Rothblat G. H. Importance of different pathways of cellular cholesterol efflux. Arterioscler Thromb Vasc Biol: 2003; 23 5 712 719
85. Nonomura K., Arai Y., Mitani H., Abe-Dohmae S., Yokoyama S. Insulin down-regulates specific activity of ATP-binding cassette transporter A1 for high density lipoprotein biogenesis through its specific phosphorylation. Atherosclerosis: 2011; 216 2 334 341
86. Ng D. S. The role of lecithin:cholesterol acyltransferase in the modulation of cardiometabolic risks-a clinical update and emerging insights from animal models. Biochim Biophys Acta: 2012; 1821 654 659
87. Tzotzas T., Desrumaux C., Lagrost L. Plasma phospholipid transfer protein (PLTP): review of an emerging cardiometabolic risk factor. Obes Rev: 2009; 10 4 403 411
88. Rothblat G. H., de la Llera-Moya M., Atger V., Kellner-Weibel G., Williams D. L., Phillips M. C. Cell cholesterol efflux: integration of old and new observations provides new insights. J Lipid Res: 1999; 40 5 781 796
89. Tall A. R., Yvan-Charvet L., Terasaka N., Pagler T., Wang N. HDL, ABC transporters, and cholesterol efflux: implications for the treatment of atherosclerosis. Cell Metab: 2008; 7 5 365 375
90. Cuchel M., Rader D. J. Macrophage reverse cholesterol transport: key to the regression of atherosclerosis? Circulation: 2006; 113 21 2548 2555
91. Khera A. V., Cuchel M., de la Llera-Moya M., et al. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med: 2011; 364 2 127 135
92. Barter P. J., Brewer H. B. Jr, Chapman M. J., Hennekens C. H., Rader D. J., Tall A. R. Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis. Arterioscler Thromb Vasc Biol: 2003; 23 2 160 167
93. Charles M. A., Kane J. P. New molecular insights into CETP structure and function: a review. J Lipid Res: 2012; 53 8 1451 1458
94. Hewing B., Fisher E. A. Rationale for cholesteryl ester transfer protein inhibition. Curr Opin Lipidol: 2012; 23 4 372 376
95. Acton S., Rigotti A., Landschulz K. T., Xu S., Hobbs H. H., Krieger M. Identification of scavenger receptor SR-BI as a high density lipoprotein receptor. Science: 1996; 271 5248 518 520
96. Silver D. L. A carboxyl-terminal PDZ-interacting domain of scavenger receptor B, type I is essential for cell surface expression in liver. J Biol Chem: 2002; 277 37 34042 34047
97. Xiao C., Watanabe T., Zhang Y., et al. Enhanced cellular uptake of remnant high-density lipoprotein particles: a mechanism for high-density lipoprotein lowering in insulin resistance and hypertriglyceridemia. Circ Res: 2008; 103 2 159 166